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Abstract 
Background: Recent experimental studies have revealed that n-3 fatty acids, such as eicosapentaenoic acid (EPA) 
regulate postprandial insulin secretion, and correct postprandial glucose and lipid abnormalities. However, the effects 
of 6-month EPA treatment on postprandial hyperglycemia and hyperlipidemia, insulin secretion, and concomitant 
endothelial dysfunction remain unknown in patients with impaired glucose metabolism (IGM) and coronary artery 
disease (CAD).
Methods and results: We randomized 107 newly diagnosed IGM patients with CAD to receive either 1800 mg/day 
of EPA (EPA group, n = 53) or no EPA (n = 54). Cookie meal testing (carbohydrates: 75 g, fat: 28.5 g) and endothelial 
function testing using fasting-state flow-mediated dilatation (FMD) were performed before and after 6 months of 
treatment. The primary outcome of this study was changes in postprandial glycemic and triglyceridemic control and 
secondary outcomes were improvement of insulin secretion and endothelial dysfunction. After 6 months, the EPA 
group exhibited significant improvements in EPA/arachidonic acid, fasting triglyceride (TG), and high-density lipopro-
tein cholesterol (HDL-C). The EPA group also exhibited significant decreases in the incremental TG peak, area under 
the curve (AUC) for postprandial TG, incremental glucose peak, AUC for postprandial glucose, and improvements 
in glycometabolism categorization. No significant changes were observed for hemoglobin A1c and fasting plasma 
glucose levels. The EPA group exhibited a significant increase in AUC-immune reactive insulin/AUC-plasma glucose 
ratio (which indicates postprandial insulin secretory ability) and significant improvements in FMD. Multiple regression 
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Cardiovascular Diabetology
*Correspondence:  taktak319@yahoo.co.jp 
1 Division of Cardiovascular Medicine, Department of Internal Medicine, 
Hyogo Prefectural Himeji Cardiovascular Center, 520 Saisho-Kou, Himeji, 
Hyogo 670-0981, Japan
Full list of author information is available at the end of the article
Page 2 of 14Sawada et al. Cardiovasc Diabetol  (2016) 15:121 
Background
Type 2 diabetes mellitus (DM) is a prevalent disease and 
recognized as a major risk factor for coronary artery 
disease (CAD) [1, 2]. Epidemiological studies and meta-
analyses indicate that dietary modifications that increase 
the relative abundance of dietary n-3 polyunsaturated 
fatty acids (PUFA), such as eicosapentaenoic acid (EPA) 
and docosahexaenoic acid, can reduce the risks of DM as 
well as CAD [3–5] Most animal experiments also docu-
ment beneficial effects of n-3 PUFA on insulin sensitiv-
ity, secretion, and glucose metabolism under condition of 
obesity, insulin resistance and DM [6, 7]. These findings 
suggest that n-3 PUFA may help control and prevent DM 
possibly due to improvement of insulin secretion and 
sensitivity.
However, data from clinical trials have been conflicting. 
Some studies indicated that n-3 PUFA improved insu-
lin sensitivity in humans, whereas others found that n-3 
PUFA had no insulin sensitizing effects [8]. Laria et  al. 
reported that dietary EPA and docosahexaenoic acid did 
not alter peripheral insulin sensitivity, postprandial glu-
cose disposal, or insulin secretion in insulin-resistant, 
non-diabetic overweight individual [9]. In contrast, a 
randomized clinical trial in overweight patients with DM 
revealed a beneficial effect of purified EPA on glucose 
homeostasis and insulin sensitivity [10]. Thus, the effect 
of EPA on the prevention or exacerbation of DM still 
remains unknown and has not yet been studied in clini-
cal intervention trials in high-risk patients with impaired 
glucose metabolism (IGM). We hypothesized that long-
term EPA treatment would predominantly improve 
postprandial state of insulin secretion and postprandial 
hyperglycemia and hypertriglyceridemia, and lead to 
prevent development of DM in patients with newly diag-
nosed IGM. In addition, these metabolic effects would be 
associated with improvement in concomitant endothelial 
dysfunction. Therefore, the present study was designed to 
examine the effects of EPA on postprandial plasma meta-
bolic parameters and fasting endothelial function among 
newly diagnosed IGM patients with CAD.
Methods
Participants
This study was open label, single blinded, randomized 
controlled study approved by the Ethics Committee of 
Hyogo Prefectural Himeji Cardiovascular Center and 
complied with the Declaration of Helsinki. Informed 
written consent was obtained from all eligible patients 
before randomization to either EPA treatment or non-
EPA treatment groups. This study is registered in the 




All potential participants who had documented chronic 
CAD, and with hemoglobin A1c levels <6.5 % (using the 
National Glycohemoglobin Standardization Program 
method), fasting plasma glucose (PG) levels ≥116 mg/dL 
or fasting plasma triglyceride (TG) levels ≥150 mg/dL by 
screening laboratory examination, were recruited from 
outpatients between July 2013 and December 2014. CAD 
was defined as stenosis of >50 % of the diameter of a cor-
onary artery on angiography or computed tomography 
coronary angiography, or a history of myocardial infarc-
tion, percutaneous coronary intervention, or coronary 
artery bypass surgery. They underwent a 75-g oral glu-
cose tolerance test (OGTT) and were diagnosed with DM 
or impaired glucose tolerance (IGT) according to Japan 
Diabetic Society criteria (DM: fasting PG  ≥126  mg/
dL and PG  ≥200  mg/dL at 2  h after the OGTT; IGT: 
PG ≥140  mg/dL at 2  h after the OGTT). Patients were 
eligible to participate if they had newly diagnosed IGM 
(defined as IGT or DM during the OGTT). The exclu-
sion criteria were presence of established DM, treat-
ment history by anti-diabetic agent, systemic disease, 
including hepatic disease, renal disease (serum creatinine 
levels ≥2.5 mg/dL), collagen disease, infection, or malig-
nancy and acute coronary syndrome.
As shown in Fig.  1, 155 patients underwent OGTT 
screening, and 118 patients were diagnosed with IGM. At 
enrollment, all patients met at least once with a dietician 
analysis revealed that decreases in the TG/HDL-C ratio and incremental TG peak were independent predictors of FMD 
improvement in the EPA group.
Conclusions: EPA corrected postprandial hypertriglyceridemia, hyperglycemia and insulin secretion ability. This ame-
lioration of several metabolic abnormalities was accompanied by recovery of concomitant endothelial dysfunction in 
newly diagnosed IGM patients with CAD.
Clinical Trial Registration UMIN Registry number: UMIN000011265 (https://www.upload.umin.ac.jp/cgi-open-bin/ctr/
ctr.cgi?function=brows&action=brows&type=summary&recptno=R000013200&language=E)
Keywords: Eicosapentaenoic acid, Impaired glucose metabolism, Postprandial hyperglycemia, Postprandial insulin 
secretion, Postprandial hypertriglyceridemia, Endothelial dysfunction
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for nutritional guidance and were encouraged to start 
and maintain a low-calorie diet and mild-to-moderate 
exercise levels. And then, 118 patients were randomly 
assigned to the EPA group (59 patients) or the non-EPA 
group (59 patients). Randomization was performed by 
means of random, permuted blocks of four in sealed 
envelope. We used EPADEL soft capsule (Mochida Phar-
maceutical Co. Ltd., Tokyo, Japan) containing 900 mg of 
highly (≥98  %) purified EPA ethyl ester per capsule. In 
this drug product, EPA is actually purified from long-
chain polyunsaturated fatty acids present in fish oil. We 
adopted the most widely used therapeutic dose of 900 mg 
of EPA ethyl ester capsule administered orally twice a day 
immediate after meals, as these dose of EPA has been 
shown to possess the beneficial effects in humans [11, 
12].
All patients were followed without hypoglycemic drugs 
and insulin treatment during the study period. And all 
participants were also requested to maintain any con-
comitant drug treatment throughout the study. At each 
visit, we questioned the participants regarding any 
adverse events.
Anthropometric measurements (body weight and body 
mass index) and systolic and diastolic blood pressures 
were measured at randomization and after 6  months of 
treatment. Blood pressure was measured with the patient 
in the supine position after 15 min of rest.
Blood biochemistry
Blood samples were collected from all patients after an 
overnight fast and were used to determine PG, hemo-
globin A1c, 1,5-anhydro-glucitol, immune reactive 
insulin (IRI), total cholesterol, high-density lipoprotein 
cholesterol (HDL-C), low-density lipoprotein (LDL) 
cholesterol, TG, remnant-like particle cholesterol, and 
C-reactive protein. All biochemical analyses were per-
formed using a commercially available kit. Hemoglobin 
A1c levels were measured using high-performance liq-
uid chromatography. IRI concentrations were measured 
using a chemiluminescent enzyme immunoassay and 
remnant-like particle cholesterol was measured using 
an assay kit (Japan Immunoresearch Laboratories Co., 
Ltd., Takasaki, Japan). Plasma total fatty acid concen-
trations were measured by a central laboratory (BML 
Inc. Saitama, Japan), which was previously described 
[12, 13]. Plasma fatty acid composition was determined 
by capillary gas chromatography. Briefly, plasma lipids 
were extracted by Folch’s procedure, and then fatty acids 
were methylated with boron trifluoride and metha-
nol, and methylated fatty acids were analyzed using the 
Fig. 1 Flow chart of patient recruitment and participation
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SHIMAZU GC-17A gas chromatograph (Shimazu Cor-
poration, Kyoto, Japan) and a BPX70 capillary column 
(0.25  mm ID*30  m; SGE international Ltd., Melbourne, 
Australia) [13].
Cookie meal test
A cookie meal test (CMT) was performed for glucose 
and fat loading at randomization and 6-month follow-up. 
The cookie consisted of carbohydrates (75  g; 85  % flour 
starch, 15 % maltose), butter fat (28.5 g), and protein (8 g) 
with 592 kcal (SARAYA Corp., Osaka, Japan). The CMT 
is sufficient for providing information regarding glucose 
intolerance and postprandial hypertriglyceridemia. The 
same values of cut-off point is proposed to be used at 
2h PG for the evaluation of DM and IGT as WHO crite-
ria for OGTT with the exception of exocrine pancreatic 
dysfunction [14]. Therefore, we used the CMT to simul-
taneously evaluate postprandial hyperglycemia (using 
the same criteria as for the OGTT) and postprandial 
hypertriglyceridemia.
All participants completed a 12-h overnight fast before 
the CMT. The cookie was ingested with water within a 
20-min period, and blood samples for PG, IRI, and TG 
measurement were obtained at 0, 1 and 2  h after the 
participant had ingested half volume of the cookie [14]. 
These values were reported as PG-1h, PG-2h, IRI-1h, IRI-
2h, TG-1h and TG-2h, respectively.
As an index of postprandial hyperglycemia, we cal-
culated the incremental glucose peak [(the maximal 
incremental increase in PG at any point after meal load-
ing)—(fasting PG)]. We also calculated the area under the 
response curves for PG (AUC-PG) and IRI (AUC-IRI) 
using the trapezoid rule. And then, we calculated AUC-
IRI/AUC-PG as an index of postprandial insulin secre-
tion ability. The homeostasis model assessment ratio 
(HOMA-R =  fasting IRI ×  fasting PG/405) was used as 
an index of insulin resistance.
Incremental TG peak [(the maximal incremental 
increase in TG at any point after loading)—(fasting TG)] 
was calculated as an index of postprandial hypertriglyc-
eridemia. The trapezoid rule was used to calculate the 
area under the TG-response curve (AUC-TG).
Small dense LDL particles, which are more susceptible 
to oxidation, have been suggested to be more atherogenic 
than large buoyant LDL [15, 16]. In this study, the TG/
HDL-C ratio was used to assess the presence of small 
dense LDL particles [17].
Measurement of endothelial function
We selected percent change in flow-mediated dilatation 
(FMD) as the surrogate marker for endothelial function 
[18–20] Before undergoing FMD testing, the participants 
were instructed to fast for >12 h and to abstain from any 
medications, smoking, alcohol, caffeine, and antioxidant 
vitamins during that time. All participants rested for at 
least 15 min in a seated position in a quiet dark air-condi-
tioned room (22–25 °C) before the FMD measurements, 
which was previously described [18, 19]. In brief, a lon-
gitudinal image of the right or left brachial artery was 
recorded at baseline using high-resolution ultrasonogra-
phy and a 10-MHz linear array transducer probe (UNEX, 
Nagoya, Japan). A forearm-cuff was inflated for 5 min at 
50  mmHg above the systolic blood pressure just prior 
to FMD measurement. After cuff deflation, the diastolic 
diameter of the brachial artery was semi-automatically 
and continuously recorded for 2  min using software-
equipped instrument that could monitor arterial diam-
eter. The %FMD was estimated as the percent change in 
the vessel diameter, which corresponded to the maxi-
mum dilatation that was reached during reactive hyper-
emia divided by the baseline value. Because the %FMD 
value is highly dependent on the baseline diameter of the 
vessel, we compared the baseline diameters and absolute 
changes in the brachial artery’s diameters for each group. 
We have also previously confirmed that there is excel-
lent intra- and inter-observed agreement for the %FMD 
measurement [18, 19].
Primary and secondary endpoints
The primary endpoint of this study was postprandial 
changes in glucose concentration (incremental glucose 
peak) and postprandial changes in TG (incremental TG 
peak), derived from CMT after 6  months treatment of 
EPA. The secondary endpoints was improvement in 
postprandial insulin secretion ability and concomitant 
endothelial dysfunction.
Statistical analysis
All statistical analyses were performed using MedCalc 
software (Version 9.3; Mariakerke, Belgium), and a two-
tailed P < 0.05 was considered statistically significant.
Sample size was determined by power analysis using 
preliminary data obtained in our laboratory with the fol-
lowing assumptions: Type I error of 0.05 (two-tailed), 
power of 90 %, difference in the incremental glucose peak 
and incremental TG peak between before and after EPA 
treatment of 20 and 20 mg/dL, respectively, and a stand-
ard deviation of 30 and 25, respectively. Therefore, a min-
imum of 31 patients would yield 90 % power to detect a 
significant difference.
All variables were checked for normal distribution 
using Kolmogorov–Smirnov algorithm. Continuous 
variables with normal distribution were reported as 
mean  ±  standard deviation, otherwise as median and 
interquartile ranges. Inter-group comparisons of nor-
mal distributed data were performed using the unpaired 
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Student’s t test, and Mann–Whitney test was used if the 
variables did not indicate normal distribution. Compari-
son of categorical variables was performed using χ2 test. 
Differences between the biochemical data with normal 
distribution before and after treatment were compared 
using a paired t test, otherwise using the Wilcoxon rank-
sum test. Multivariable regression analyses were used to 
identify factors that were independently associated with 
the changes in incremental glucose peak and %FMD. 
Biologically plausible factors were included in the origi-
nal model. Potential factors of interest with a univariate 
P ≤ 0.1 were entered into multivariate models.
Results
Study population
Among the 118 eligible patients, five patients in the EPA 
group and six patients in the non-EPA group withdrew 
their consent before second CMT. Therefore, the final 
analyses included data from 54 patients in the EPA group 
and 53 patients in the non-EPA group (Fig. 1).
During the study period, one patient in the EPA group 
and one patient in the non-EPA group underwent per-
cutaneous coronary intervention due to progression of 
CAD. However, there were no major adverse events such 
as massive bleeding complication and gastrointestinal 
disorder requisite to treat that were related to the EPA 
treatment.
Baseline characteristics, laboratory data, 
and anthropometric measurements
As shown in Table 1, the patients’ baseline characteristics 
and concomitant drug use were similar for groups. Most 
baseline laboratory findings were similar between the 
two groups, although fasting PG levels in the EPA group 
were lower than those in the non-EPA group. At baseline, 
resting brachial artery diameters and levels of endothelial 
function impairment were similar between the two 
groups. After 6  months treatment, both groups exhib-
ited significant reductions in body weight and body mass 
index although there were no significant inter-group dif-
ferences in these changes (Table 2).
Changes in fasting lipid and glucose profiles
The fasting lipid and glucose profiles at baseline and 
6 months are shown in Table 3. After 6 months of treat-
ment, the median EPA/arachidonic acid (AA) ratio sig-
nificantly increased in the EPA group (from 0.31 to 1.08, 
P  <  0.0001), and significantly increased HDL-C levels 
also occurred in the EPA group. Significant reductions 
in the levels of LDL cholesterol, TG, TG/HDL-C ratio, 
and remnant-like particle cholesterol were observed in 
the EPA group, but not in the non-EPA group. The EPA 
group exhibited significantly increased 1,5-anhydro-glu-
citol levels, although no changes were observed in the 
non-EPA group. The changes of TG, TG/HDL-C ratio 
and 1,5-anhydro-glucitol levels from baseline were also 
significantly larger in the EPA group than the non-EPA 
group. Neither group exhibited significant changes in 
fasting levels of PG, IRI, hemoglobin A1c, and HOMA-R.
Changes in the CMT results
The CMT data from baseline and after 6 months of treat-
ment are shown in Figs.  2, 3 and Table  4. The baseline 
CMT revealed that, among patients from the non-EPA 
group, 37 patients (69.8  %) had IGT and 16 patients 
(30.2  %) had DM. Similarly, among patients from the 
EPA group, 38 patients (70.4 %) had IGT and 16 patients 
(29.6 %) had DM (Fig. 2). After 6 months, the EPA group 
included 16 patients (29.6 %) with normal glucose toler-
ance, 31 patients (57.4  %) with IGT and seven patients 
(13.0  %) with DM. The non-EPA group included three 
patients (5.7  %) with normal glucose tolerance, 35 
Table 1 Comparison of baseline characteristics and concomitant use drugs between the two groups
Values are presented as number (%) or mean ± standard deviation, as indicated
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker
Non-EPA group (n = 53) EPA group (n = 54) P value
Age (y.o) 68.9 ± 8.8 67.8 ± 9.1 0.49
Sex (male, n, %) 43 (81.1 %) 44 (81.5 %) 0.84
Coronary risk factor
 Hypertension (n, %) 49 (92.5 %) 48 (88.9 %) 0.76
 Dyslipidemia (n, %) 53 (100 %) 54 (100 %) 0.99
 Smoking (n, %) 4 (7.5 %) 5 (9.3 %) 0.98
Concomitant use drug
 Statin (n, %) 44 (83.0 %) 46 (85.2 %) 0.97
 Calcium channel blocker (n, %) 30 (56.6 %) 27 (50.0 %) 0.62
 ACEI/ARB (n, %) 35 (66.0 %) 40 (74.1 %) 0.49
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patients (66.0 %) with IGT and 15 patients (28.3 %) with 
DM. With regard to changes in glucometabolic category, 
deteriorated patients were significantly larger in the non-
EPA group, while improved patients were significantly 
larger in the EPA group (deteriorated glucose tolerance; 
seven patents in the non-EPA group vs two patients in 
the EPA group, improved glucose tolerance; 11 patients 
in the non-EPA group vs 25 patients in the EPA group, 
p = 0.01).
Significant reductions in AUC-PG and incremental glu-
cose peak were only observed for the EPA group (Table 4; 
Fig. 3). Despite significant improvements in AUC-PG, the 
EPA group exhibited a mild increase in AUC-IRI, while 
the non-EPA group exhibited decreased AUC-IRI accom-
panied by AUC-PG decrease (Fig. 3). Thus, the AUC-IRI/
AUC-PG ratio, which indicated postprandial insulin secre-
tion ability, significantly increased only in the EPA group.
Compared to baseline data, the EPA group exhibited 
significant reductions in TG-1h, TG-2h, and fasting TG 
levels. Furthermore, incremental TG peak and AUC-TG 
decreased only in the EPA group.
As for the comparison of absolute change from base-
line between the EPA and non-EPA groups, the changes 
of PG-1h, PG-2h, AUC-PG, incremental glucose peak, 
fasting TG, TG-1h, TG-2h, AUC-TG, and incremental 
TG peak were significantly higher in the EPA group than 
the non-EPA group. Furthermore, the changes of AUC-
IRI/AUC-PG ratio from baseline was significantly larger 
in the EPA group than the non-EPA group.
The multiple regression analysis showed that EPA 
treatment and lower baseline PG levels were independent 
factor for predicting improvement of incremental glucose 
peak (Additional file 1: Table S1). In order to adjust the 
difference of baseline PG levels between the two groups, 
additional analysis was performed among patients with 
similar baseline PG levels of  ≤110  mg/dL (Additional 
file  2: Table S2). The absolute changes of incremental 
glucose and TG peak in the EPA group remained larger 
than those in the non-EPA group, and also the change of 
AUC-IRI/AUC-PG ratio in the EPA group was signifi-
cantly higher than that in the non-EPA group.
Comparing inflammatory markers and endothelial 
function
As shown in Table 3, the improvement of C-reactive pro-
tein levels was significantly higher in the EPA group than 
in the non-EPA group (P = 0.05). Although both groups 
exhibited impaired endothelial function at baseline, the 
EPA group exhibited a significant improvement in %FMD 
after 6  months of treatment. In contrast, endothelial 
dysfunction was unchanged in the non-EPA group. The 
results of the univariate and multivariate regression anal-
yses for predicting improvements in %FMD are shown 
in Table 5. In the EPA group, improvements in the TG/
HDL-C ratio and incremental TG peak were independent 
predictors of %FMD improvements.
Discussion
Six months of EPA treatment improved not only fasting 
atherogenic lipid derangements and postprandial hyper-
triglyceridemia, but also postprandial hyperglycemia and 
insulin secretion ability. The simultaneous improvements 
in several metabolic abnormalities were associated with 
improvements in concomitant endothelial dysfunction 
among newly diagnosed IGM patients with CAD who 
received EPA.
Table 2 Comparison of  anthropometric analysis between  baseline and  6  months, and  comparison of  absolute change 
from baseline between the two groups
P values represent comparison of each values between groups at 6 months except for absolute Δ
As for absolute Δ of each values, P values represent comparison between the two groups
Values are presented as mean ± standard deviation or medians and interquartile ranges, as indicated
* P < 0.001 vs baseline
Variable Non-EPA group (n = 53) EPA group (n = 54) P value
Baseline 6-month Baseline 6-month
Weight (kg) 67.8 ± 10.0 66.3 ± 9.9* 67.6 ± 11.2 66.4 ± 11.0* 0.97
 Absolute Δ −1.1 (−3.0, 0.0) −1.0 (−2.8, 0.0) 0.49
Body mass index (kg/m2) 25.4 ± 2.4 24.8 ± 2.4* 25.3 ± 2.9 24.8 ± 2.8* 0.90
 Absolute Δ −0.5 (−1.1, 0.0) −0.4 (−1.0, 0.0) 0.53
Systolic blood pressure (mmHg) 135.6 ± 15.0 133.0 ± 17.1 132.9 ± 19.5 129.7 ± 19.0 0.35
 Absolute Δ −3.0 (−13.0, 8.0) −3.0 (−10.0, 4.0) 0.89
Diastolic blood pressure (mmHg) 78.6 ± 9.8 77.5 ± 10.9 77.2 ± 11.7 76.3 ± 8.2 0.51
 Absolute Δ −2.0 (−7.0, 3.3) 0.0 (−7.0, 6.0) 0.63
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Table 3 Comparison of biochemical data and flow-mediated dilatation data between baseline and 6 months, and com-
parison of absolute change from baseline between the two groups
P values represent comparison of each values between groups at 6 months except for absolute Δ
As for absolute Δ of each values, P values represent comparison between the two groups
Values are presented as mean ± standard deviation or medians and interquartile ranges, as indicated
PG plasma glucose, IRI immune reactive insulin, HOMA-R homeostasis model assessment ratio, LDL low-density lipoprotein, HDL-C high-density lipoprotein 
cholesterol, TG triglyceride, EPA eicosapentaenoic acid, AA arachidonic acid, FMD flow-mediated dilatation
†  P < 0.05 vs baseline values of non-EPA group
* P < 0.05 vs baseline, ** P < 0.01 vs baseline, *** P < 0.0001 vs baseline
Variable Non-EPA group (n = 53) EPA group (n = 54) P value
Baseline 6-month Baseline 6-month
Fasting PG (mg/dL) 111.2 ± 10.4 109.9 ± 10.8 105.8 ± 11.1† 104.5 ± 9.1 0.001
 Absolute Δ −1.0 (−6.0, 4.0) −1.0 (−5.0, 4.0) 0.69
Hemoglobin A1c (NGSP; %) 6.1 ± 0.4 6.1 ± 0.4 6.0 ± 0.3 5.9 ± 0.4 0.02
 Absolute Δ 0.0 (−0.1, 0.13) 0.0 (−0.1, 0.10) 0.49
1,5-anhydro-glucitol (μg/mL) 16.5 ± 6.1 16.1 ± 6.4 18.5 ± 7.8 19.3 ± 8.0* 0.02
 Absolute Δ −0.6 (−1.8, 1.2) 0.9 (−0.8, 1.9) 0.03
Fasting IRI (µU/mL) 6.4 ± 3.3 6.1 ± 2.9 6.6 ± 3.4 6.5 ± 3.0 0.49
 Absolute Δ −0.1 (−1.4, 0.7) −0.2 (−2.0, 1.8) 0.63
HOMA-R 1.6 (1.0, 2.4) 1.6 (1.1, 2.0) 1.6 (1.0, 2.3) 1.6 (1.0, 2.2) 0.86
 Absolute Δ 0.0 (−0.4, 0.2) 0.0 (−0.5, 0.5) 0.67
Total cholesterol (mg/dL) 171.7 ± 31.9 169.1 ± 27.7 171.8 ± 30.8 167.4 ± 29.4 0.76
 Absolute Δ −1.0 (−12.5, 8.5) −3.5 (−13.0, 7.0) 0.45
LDL cholesterol (mg/dL) 96.7 ± 25.1 95.5 ± 23.3 97.9 ± 27.6 92.5 ± 26.8** 0.53
 Absolute Δ 1.0 (−10.2, 8.0) −4.0 (−13.0, 3.0) 0.09
HDL-C (mg/dL) 48.2 ± 9.8 48.2 ± 11.6 46.7 ± 9.3 50.1 ± 13.2** 0.51
 Absolute Δ 0.0 (−4.3, 3.0) 2.0 (−3.0, 8.0) 0.05
TG (mg/dL) 123.3 ± 59.2 120.8 ± 62.2 137.8 ± 67.6 103.0 ± 38.1*** 0.10
 Absolute Δ −3.0 (−35.0, 19.0) −24.0 (−54.0, −3.0) 0.005
TG/HDL-C ratio 2.46 (1.43, 3.54) 2.18 (1.38, 3.54) 2.58 (1.65, 4.63) 2.02 (1.35, 2.65)*** 0.39
 Absolute Δ −0.04 (−0.72, 0.33) −0.73 (−1.44, −0.12) 0.0004
Remnant-like particle-cholesterol (mg/dL) 9.1 ± 6.1 8.4 ± 6.1 10.4 ± 6.4 7.3 ± 3.9*** 0.26
 Absolute Δ −1.0 (−3.1, 1.1) −1.7 (−4.8, −0.3) 0.07
EPA (μg/mL) 84.0 ± 50.7 81.1 ± 45.0 69.3 ± 40.7 196.4 ± 51.4*** <0.0001
 Absolute Δ −1.0 (−23.5, 24.0) 128.0 (98.0, 164.0) <0.0001
AA (μg/mL) 205.6 ± 55.3 201.2 ± 48.1 206.3 ± 52.6 177.0 ± 39.7*** 0.006
 Absolute Δ −2.0 (−34.8, 22.5) −30.0 (−52.0, −3.0) 0.001
Docosahexaenoic acid (μg/mL) 162.5 ± 64.6 152.2 ± 57.7 158.9 ± 70.0 134.2 ± 48.1** 0.08
 Absolute Δ −18.0 (−44.3, 15.8) −21.5 (−55.0, 12.0) 0.27
EPA/AA ratio 0.35 (0.25, 0.52) 0.36 (0.27, 0.46) 0.31 (0.21, 0.49) 1.08 (0.88, 1.45)*** <0.0001
 Absolute Δ −0.01 (−0.11, 0.10) 0.78 (0.52, 1.05) <0.0001
Docosahexaenoic acid/AA 0.75 (0.59, 1.02) 0.74 (0.63, 0.96) 0.78 (0.53, 0.97) 0.77 (0.56, 0.95) 0.92
 Absolute Δ −0.01 (−0.19, 0.11) −0.01 (−0.15, 0.11) 0.71
C-reactive protein (mg/dL) 0.09 (0.04, 0.14) 0.06 (0.04, 0.12) 0.10 (0.04, 0.22) 0.06 (0.03, 0.11)*** 0.55
 Absolute Δ −0.01 (−0.05, 0.02) −0.01 (−0.08, 0.00) 0.05
%FMD (%) 4.1 ± 1.8 4.0 ± 1.6 3.6 ± 1.7 5.2 ± 1.9*** 0.0005
 Absolute Δ 0.1 (−0.6, 0.8) 1.6 (0.7, 2.5) <0.0001
Rest brachial artery diameter (mm) 4.27 ± 0.55 4.23 ± 0.58 4.23 ± 0.60 4.23 ± 0.58 0.72
 Absolute change in brachial artery diameter 
(mm)
0.17 ± 0.07 0.17 ± 0.06 0.15 ± 0.07 0.22 ± 0.07*** 0.0005
 Absolute Δ 0.01 (−0.03, 0.03) 0.06 (0.02, 0.08) <0.0001
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Effects of EPA on postprandial hyperglycemia
Accumulating data from animal models confirm that n-3 
PUFA have numerous beneficial effects on health and dis-
eases, such as anti-arrhythmic, vasodilatory, anti-inflam-
matory, anti-thrombotic, and lipid lowering actions 
[21–23]. N-3 PUFA also have a number of metabolic 
effects including improvement in insulin secretion, sen-
sitivity and anti-obesity action [7, 8]. The recent experi-
ments have revealed that n-3 PUFA act as ligands of 
several G-protein- coupled receptors (GPCRs) including 
GPCR 40 on pancreatic β cells and GPCR 120 on enter-
oendocrine cells of gastrointestinal tract [24, 25]. These 
actions enforce the beneficial effects on insulin secre-
tion and sensitivity, and glucose homeostasis. However, 
many previous clinical trials have reported inconsistent 
results regarding the association of n-3 PUFA intake with 
the incidence of DM and glycemic control [8–10]. In the 
present study, we found that EPA treatment resulted in 
significant improvements in postprandial insulin secre-
tion and glucose homeostasis among patients with IGM 
and significantly ameliorated the development of DM. 
Although we did not assess glucagon-like peptide-1 con-
centrations, we speculate that EPA-activated GPCRs 
might be actively involved in postprandial insulin secre-
tion. These results suggest that EPA might provide a 
greater protective effect against developing DM among 
pre-diabetic patients. The results from the Japan EPA 
Lipid Intervention Study (JELIS) trial [11] support this 
possibility, as long-term treatment with EPA resulted in a 
significant 33 % reduction in the incidence of new-onset 
DM among patients with IGM (U.S. Patent Application 
Publication No. US2015/0250754 A1).
Although a few previous studies have reported that 
n-3 PUFA improved insulin resistance [10], we did not 
observe any significant improvement in HOMA-R for 
the EPA group. There are two possible explanations for 
this finding. First, our mean pre-treatment HOMA-
R was 1.6, which was near the upper limit for normal 
HOMA-R results in the Japanese population, and might 
preclude the detection of any significant change. Second, 
EPA treatment did not alter fasting glycemic control at 
6 months. Because HOMA-R was calculated using fast-
ing PG and insulin levels, EPA treatment did not signifi-
cantly improve HOMA-R. Many human studies have also 
failed to demonstrate that n-3 PUFA exert a protective 
effect on insulin sensitivity [8, 9]. Thus, future studies 
should be warranted in selected study populations.
Most trials have involved the use of diets supplemented 
by intake of fish, fish oil or capsule containing fish oil 
extracts. These contains a number of other fatty acids and 
different components. Thus, an evaluation of the specific 
effects of each n-3 PUFA was not possible. We adopted 
highly purified EPA ethyl ester, which was approved by 
Japan’s Ministry of Health, Labour and Welfare for the 
treatment of peripheral artery disease and hyperlipi-
demia, to examine its effects on postprandial glucose and 
insulin metabolism [11, 12].
Effects of EPA on atherogenic dyslipidemia 
and postprandial hypertriglyceridemia
Despite best evidence-based statin therapy, it is clear 
that there persists unacceptably high residual cardiovas-
cular events [26]. The importance of atherogenic dys-
lipidemia, defined as elevated TG-rich lipoproteins and 
their remnants and low HDL-C, has been recognized as 
a key driver of residual cardiovascular risk in individu-
als with metabolic disease, even if LDL cholesterol are 
well controlled [26, 27]. Type 2 DM commonly repre-
sents elevated TG, low HDL-C, and the predominance of 
small dense LDL particles due to insulin resistance [28]. 
Thereby, patients with DM are thought to belong to the 
highest cardiovascular disease risk category despite being 
treated by statin [1, 2, 29].
Several methods have been developed for the measure-
ment of atherogenic small dense LDL levels, including 
ultracentrifugation, gradient gel electrophoresis, nuclear 
magnetic resonance spectroscopy and heparin magne-
sium precipitation methods [30, 31]. However, there is no 
standard procedure for clinical practice. Maruyama et al. 
demonstrated that the TG/HDL-C ratio was associated 
with LDL particle size [17]. Previous reports revealed 
that a high TG/HDL-C ratio was associated with cardio-
vascular disease and all-cause death among patients with 
Fig. 2 Categorical allocation according to glucose tolerance at 
baseline and after 6 months. Numbers on the lines represent the 
number of patients transferred between glucose categories. Deterio-
rated patients were significantly larger in the non-EPA group, while 
improved patients were significantly larger in the EPA group (deterio-
rated glucose tolerance; seven patents in the non-EPA group vs two 
patients in the EPA group, improved glucose tolerance; 11 patients 
in the non-EPA group vs 25 patients in the EPA group, p = 0.01). 
Comparison was performed using χ2 test
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DM or metabolic syndrome [17, 32, 33] and the amelio-
ration of this abnormality was associated with improve-
ments in endothelial dysfunction [34]. Thus, high TG/
HDL-C ratio was regarded as an important residual car-
diovascular risk and a therapeutic target for decreasing 
cardiovascular events in DM patients. Therefore, we used 
the TG/HDL-C ratio as the marker of small dense LDL 
particle in this study.
Long-term ingestion of fish oils (which include n-3 
PUFA) by normal volunteers and patients with hyper-
triglyceridemia dramatically reduced fasting TG levels 
and postprandial hyperlipidemia that were produced by 
fat loading [35, 36]. In this context, n-3 PUFA have been 
suggested to predominantly suppress both hepatic and 
intestinal ApoB secretion and synthesis. EPA treatment 
also reduced TG levels with minimal changes in HDL-C 
levels for both healthy volunteers and patients with CAD 
[11, 21–23] and significantly decreased postprandial 
TG elevation and concomitantly improved postprandial 
endothelial dysfunction among healthy individuals [35]. 
The present study also revealed that 6  months of EPA 
treatment significantly reduced postprandial hypertri-
glyceridemia (incremental TG peak and AUC-TG) and 
remnant-like particle cholesterol as well as fasting TG 
levels and TG/HDL-C ratio, and that these improve-
ments were associated with improvements in endothelial 
dysfunction among patients with newly diagnosed IGM. 
Therefore, these results suggest that EPA has beneficial 
Fig. 3 Plasma glucose (PG), immune reactive insulin (IRI), and triglyceride (TG) levels during cookie meal test at baseline and 6 months. Bars indi-
cate SEM. * indicates P < 0.05 vs baseline. Comparisons of data between before and after treatment were performed using a paired t test
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effects on postprandial hypertriglyceridemia and other 
atherogenic dyslipidemia, such as remnant-like parti-
cle cholesterol and small dense LDL particles, and may 
significantly contribute to the residual risk reduction of 
cardiovascular events among patients with IGM. Indeed, 
JELIS trials have demonstrated that EPA treatment 
(1800  mg/day) significantly reduced the risk of major 
coronary events during an average follow-up of 4.6 years, 
Table 4 Comparison of  cookie meal test data between  baseline and  6  months, and  comparison of  absolute change 
from baseline between the two groups
P values represent comparison of each values between groups at 6 months except for absolute Δ
As for absolute Δ of each values, P values represent comparison between the two groups
Values are presented as mean ± standard deviation or medians and interquartile ranges, as indicated
DM diabetes mellitus, IGT impaired glucose tolerance, NGT normal glucose toleransce, PG plasma glucose, AUC area under the response curve, IRI immune reactive 
insulin, TG triglyceride
†  P < 0.05 vs baseline values of non-EPA group
* P < 0.01 vs baseline, ** P < 0.0001 vs baseline
Variable Non-EPA group (n = 53) EPA group (n = 54) P value
Baseline 6-month Baseline 6-month
Glucose tolerance test
 NGT (n, %) 0 (0.0 %) 3 (5.7 %) 0 (0.0 %) 16 (29.6 %)** 0.001
 IGT (n, %) 37 (69.8 %) 35 (66.0 %) 38 (70.4 %) 31 (57.4 %) 0.36
 DM (n, %) 16 (30.2 %) 15 (28.3 %) 16 (29.6 %) 7 (13.0 %)* 0.05
Fasting PG (mg/dL) 111.2 ± 10.4 109.9 ± 10.8 105.8 ± 11.1† 104.5 ± 9.1 0.009
 Absolute Δ −1.0 (−6.0, 4.0) −1.0 (−5.0, 4.0) 0.69
PG-1h (mg/dL) 200.3 ± 32.9 197.0 ± 33.3 190.9 ± 34.4 172.9 ± 26.8** 0.0001
 Absolute Δ −5.0 (−23.0, 14.0) −15.5 (−33.0, 1.0) 0.006
PG-2h (mg/dL) 185.1 ± 25.5 180.1 ± 30.8 179.7 ± 32.5 162.2 ± 32.9** 0.004
 Absolute Δ −9.0 (−21.3, 19.3) −18.0 (−33.0, 0.0) 0.03
AUC-PG 348.5 ± 42.1 342.0 ± 46.9 333.2 ± 48.9 306.4 ± 41.4** 0.0001
 Absolute Δ −7.0 (−13.3, 2.1) −22.3 (−45.0, 10.0) 0.002
Incremental glucose peak (mg/dL) 95.0 ± 27.7 92.1 ± 29.1 90.9 ± 30.3 75.4 ± 26.2** 0.002
 Absolute Δ −6.0 (−19.3, 15.3) −16.5 (−33.0, −2.0) 0.006
Fasting IRI (µU/mL) 6.4 ± 3.3 6.1 ± 2.9 6.6 ± 3.4 6.5 ± 3.0 0.49
 Absolute Δ −0.1 (−1.4, 0.7) −0.2 (−2.0, 1.8) 0.63
IRI-1h (µU/mL) 53.9 ± 29.7 50.7 ± 25.2 54.3 ± 32.2 57.3 ± 29.8 0.28
 Absolute Δ 0.1 (−10.6, 10.4) 0.7 (−7.0, 13.1) 0.27
IRI-2h (µU/mL) 64.4 ± 30.2 58.6 ± 27.2 61.8 ± 35.0 60.1 ± 30.5 0.78
 Absolute Δ −6.0 (−15.3, 5.2) 2.5 (−15.5, 10.9) 0.2
AUC-IRI 89.3 ± 42.1 83.0 ± 36.6 88.5 ± 48.3 89.7 ± 42.4 0.38
 Absolute Δ −3.7 (−19.5, 8.6) 4.9 (−7.4, 11.4) 0.08
AUC-IRI/AUC-PG 0.23 (0.18, 0.35) 0.24 (0.17, 0.29) 0.24 (0.17, 0.33) 0.27 (0.19, 0.36)** 0.06
 Absolute Δ −0.01 (−0.04, 0.03) 0.02 (−0.01, 0.06) 0.003
Fasting TG (mg/dL) 123.3 ± 59.2 120.8 ± 62.2 137.8 ± 67.6 103.0 ± 38.1** 0.10
 Absolute Δ −3.0 (−35.0, 19.0) −24.0 (−54.0, −3.0) 0.005
TG-1h (mg/dL) 138.5 ± 61.8 136.2 ± 64.0 150.7 ± 64.7 121.1 ± 37.7** 0.17
 Absolute Δ 0.0 (−29.5, 16.5) −20.5 (−57.0, 4.0) 0.01
TG-2h (mg/dL) 168.9 ± 74.8 171.6 ± 89.3 198.3 ± 78.7 150.8 ± 44.7** 0.14
 Absolute Δ −2.0 (−33.8, 27.3) −42.0 (−80.0, 10.0) 0.0001
AUC-TG 285.0 ± 126.5 282.0 ± 137.3 316.8 ± 135.1 250.0 ± 76.3** 0.13
 Absolute Δ −5.5 (−60.5, 37.3) −51.5 (−127.0, 5.0) 0.002
Incremental TG peak (mg/dL) 45.2 ± 31.2 51.9 ± 43.7 60.5 ± 29.8† 47.8 ± 24.7* 0.54
 Absolute Δ 4.0 (−12.0, 21.3) −11.5 (−24.0, 3.0) 0.005
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and sub-analyses revealed that EPA treatment was espe-
cially beneficial among patients with IGM or patients 
with high TG and low HDL-C levels [11, 37, 38].
Effects of EPA on FMD
Endothelial dysfunction contributes to the onset and 
progression of atherosclerosis [39]. Furthermore, 
endothelial dysfunction is associated with many cardio-
vascular risk factors, such as dyslipidemia, hypertension, 
DM, and obesity. Moreover, postprandial hyperglyce-
mia and hypertriglyceridemia cause temporal and per-
sistent endothelial dysfunction, and are thought to be 
associated with increased risk of CAD, especially among 
pre-diabetic and diabetic patients [18, 35]. The patho-
physiology of FMD, based on reactive hyperemia, has 
extensively been studied and a previous large-scale pop-
ulation-based study demonstrated that brachial FMD 
predicted the incidence of cardiovascular events among 
adults [20]. Therefore, we selected percent change in 
FMD as the surrogate marker for the risk of future car-
diovascular events.
EPA or re-composition of plasma membrane fatty 
acids following EPA administration (high EPA/AA ratio) 
directly improves endothelial dysfunction and provides a 
vasodilatory effect among patients with CAD and hyper-
lipidemia [40, 41]. Moreover, EPA upregulates endothelial 
Table 5 Regression analysis for predicting % flow-mediated dilatation improvement
PG plasma glucose, IRI immune reactive insulin, HOMA-R homeostasis model assessment ratio, AUC area under the response curve, LDL low-density lipoprotein, HDL 
high-density lipoprotein, TG triglyceride, EPA eicosapentaenoic acid, AA arachidonic acid
Variable Non-EPA group (n = 53) EPA group (n = 54)
Univariate Multivariate Univariate Multivariate
t P value t P value t P value t P value
Age 2.865 0.006 2.505 0.01 0.085 0.93 0.013 0.99
Sex −1.640 0.11 −1.038 0.30 −0.106 0.92 0.055 0.96
Changes in weight −0.123 0.90 −0.045 0.95
Changes in fasting PG 0.837 0.41 1.531 0.13
Changes in fasting IRI 0.584 0.56 1.093 0.28
Changes in Hemoglobin A1c 0.437 0.66 0.399 0.69
Changes in 1,5-anhydro-glucitol −1.463 0.15 1.542 0.13
Changes in HOMA-R 0.027 0.98 0.596 0.55
Changing in PG-1h −0.675 0.50 −1.305 0.20
Changing in PG-2h 1.776 0.08 −1.092 0.28 −0.923 0.36
Changing in AUC-PG 0.049 0.96 −0.945 0.35
Changing in incremental glucose peak −0.030 0.98 −2.227 0.03 −1.054 0.30
Changing in IRI-1h −0.896 0.37 0.008 0.99
Changing in IRI-2h 1.549 0.13 −1.156 0.25
Changing in AUC-IRI −0.154 0.88 −0.511 0.61
Changing in AUC-IRI/AUC-PG −0.276 0.78 −0.001 0.99
Changes in total cholesterol −0.680 0.50 −0.349 0.73
Changes in LDL cholesterol −0.531 0.60 0.280 0.78
Changes in HDL cholesterol −0.085 0.93 0.328 0.74
Changes in TG −1.925 0.05 0.274 0.79 −2.062 0.04
Changes in log TG/HDL ratio −1.234 0.22 −2.009 0.05 −2.001 0.05
Changing in TG2h 1.234 0.22 −3.842 0.0003
Changing in AUC-TG −2.140 0.03 −0.288 0.77 −2.727 0.009
Changing in incremental TG peak −1.413 0.16 −4.337 <0.0001 −3.560 0.0008
Changes in remnant-like particle cholesterol −2.282 0.03 −2.022 0.05 −0.369 0.71
Changes in EPA −0.269 0.79 −0.213 0.83
Changes in AA −0.174 0.86 −0.142 0.89
Changes in docosahexaenoic acid −0.752 0.46 −1.290 0.20
Changes in EPA/AA −0.469 0.64 0.109 0.91
Changes in C-reactive protein −0.560 0.58 0.328 0.74
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nitric oxide synthase and augments nitric oxide produc-
tion through the activation and translocation of endothe-
lial nitric oxide synthase in endothelial cells [42].
In the present study, we measured plasma EPA levels 
and the EPA/AA ratio to monitor the bioavailability of 
EPA. There is accumulating evidence that blood EPA lev-
els and the EPA/AA ratio predict the risk of cardiovas-
cular events among the general population and patients 
with CAD [43]. It appears that EPA possesses a variety of 
biological actions including anti-inflammatory and anti-
thrombotic effects, which may contribute to the preven-
tion of cardiovascular events [22, 23, 44, 45]. Indeed, the 
present study also revealed improvements in inflamma-
tory marker by using EPA and then improved endothe-
lial dysfunction. Furthermore, based on EPA’s beneficial 
effects on metabolic derangements and endothelial pro-
tection, it appears that n-3 PUFA may reduce the risk 
of developing DM and/or cardiovascular events among 
patients with IGM.
Effects on EPA on fasting glucose control
Most observational studies have reported an association 
between glucose control and cardiovascular disease [46]. 
Furthermore, several randomized controlled studies of 
patients with type 2 DM have demonstrated that inten-
sive glucose control was associated with a significant 
reduction in the rate of major cardiovascular events [47]. 
Therefore, glycemic control plays an important role in 
preventing CAD among patients with diabetes. However, 
the present study found no changes in the EPA group’s 
fasting PG, IRI, ad hemoglobin A1c levels after 6 months 
of treatment. In this context, the STOP-NIDDM trial 
reported that acarbose (an α-glucosidase inhibitor) 
reduced the risk of cardiovascular events among patients 
with IGT, although these patients did not experience any 
changes in their fasting PG [48]. The authors speculated 
that a reduction in postprandial hyperglycemia and TG 
levels might reduce oxidative stress and endothelial dys-
function, which would subsequently be associated with 
the prevention of cardiovascular events.
Study limitations
Several limitations in the present study warrant consid-
eration. First, this study was open-label, single-blinded 
and number of participants was relatively small. Sec-
ond, baseline PG level of the EPA group was significantly 
lower than that of the non-EPA group and multiple 
regression analysis for predicting incremental glucose 
peak improvement revealed lower baseline PG levels and 
EPA treatment. Whether the difference of baseline PG 
level between the two groups might influence the results 
of the present study was tested by additional statistical 
analysis. The improvement of incremental glucose and 
TG peak in the EPA group remained larger than that in 
the non-EPA group and the change of AUC-IRI/AUC-
PG ratio in the EPA group was significantly higher than 
that in non-EPA group even among patients with similar 
baseline PG levels ≤110 mg/dL. Therefore, these results 
supported the improvements of postprandial hypergly-
cemia, hypertriglyceridemia and insulin secretory ability 
might be due to an effect of EPA. Third, cohort studies 
have reported that n-3 PUFA consumption was inversely 
associated with the incidence of DM in Asia, whereas it 
was positively associated in North America and Europe 
[4]. Thus, our results may not generalize to other geo-
graphical or racial populations. Fourth, docosahexaenoic 
acid has an in vitro agonistic effect on GPCR 40 that is 
stronger than the effect of EPA [24], and both EPA and 
docosahexaenoic acid have numerous distinct biological 
effects. Therefore, future studies are needed to explore 
the effects of docosahexaenoic acid on the incidences of 
DM and glucose homeostasis.
Conclusions
In conclusion, EPA corrected not only postprandial 
hypertriglyceridemia but also postprandial hypergly-
cemia and insulin secretion ability. This amelioration of 
metabolic abnormalities was associated with improve-
ments in concomitant endothelial dysfunction among 
newly diagnosed IGM patients with CAD. Though life-
style changes remain a cornerstone in all strategy for pre-
vention of DM, this study suggests that addition of EPA 
could accelerate the prevention of DM and CAD.
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